Tau pathological activity in plasma before the onset of symptomatic Alzheimer's disease - PubMed
3 hours ago
- #Blood Test
- #Alzheimer's Disease
- #Tau Biomarker
- Tau hyperphosphorylation and aggregation in Alzheimer's disease (AD) predicts neurodegeneration and cognitive decline, but current detection methods like tau PET are limited by cost and accessibility.
- Plasma biomarkers like pTau217 lack specificity for AD-related tau aggregation due to heterogeneous phosphorylation patterns and can be elevated without aggregated tau.
- The VeraBIND Tau assay detects pathologically active pTau (PA pTau) seeding activity in plasma, showing 94.2% sensitivity and 96.1% specificity for tau-PET positivity (AUC=0.97).
- VeraBIND Tau outperformed plasma pTau217, especially in cognitively unimpaired individuals and early tau-PET stages (Braak stages 1-3), with higher diagnostic accuracy.
- VeraBIND Tau values and changes correlated with cognitive performance and entorhinal tau-PET signals, supporting its potential as a scalable screening tool for AD tau pathology.